Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.7113
Nov 20 • 3:59 PM ET Dollar change-0.0371 Percentage change(-4.96%)
Aftermarket Close
0.7188
Aftermarket • 7:38 PM ET Dollar change+0.0075 Percentage change(1.05%)
Nov 20, 8:05 AMAnnovis says FDA agreed to its plan to pool buntanetap safety data from Alzheimer’s and Parkinson’s studies for a planned NDA.
Index
-
Market Cap
44.12M
Enterprise Value
41.30M
Income
-51.72M
Sales
0.00M
Book/sh
-0.31
Cash/sh
0.05
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
8
IPO
Jan 29, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
15.65
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.88
Current Ratio
0.88
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-1.65
EPS next Y
-0.78
EPS next Q
-0.23
EPS this Y
6.43%
EPS next Y
40.71%
EPS next 5Y
18.25%
EPS past 3/5Y
23.23% -10.15%
Sales past 3/5Y
- -
EPS Y/Y TTM
-15.00%
Sales Y/Y TTM
-
EPS Q/Q
39.85%
Sales Q/Q
-
Insider Own
11.79%
Insider Trans
216.17%
Inst Own
19.91%
Inst Trans
-10.95%
ROA
-455.86%
ROE
-703.68%
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-21.91%
SMA50
-32.36%
SMA200
-59.77%
Trades
Shs Outstand
62.02M
Shs Float
54.71M
52W High
5.50 -87.07%
52W Low
0.62 15.45%
Volatility
15.86% 15.72%
ATR (14)
0.13
RSI (14)
38.57
Beta
1.47
Rel Volume
0.80
Avg Volume
1.79M
Volume
1,439,184
Perf Week
-23.19%
Perf Month
-28.27%
Perf Quarter
-59.35%
Perf Half Y
-68.10%
Perf YTD
-79.44%
Perf Year
-81.67%
Perf 3Y
-88.26%
Perf 5Y
-97.38%
Perf 10Y
-
Prev Close
0.75
Price
0.71
Change %
-4.96%
Consensus
Strong Buy
Avg. Price Target
$9.50
Implied Upside
+1,235.6%
Analysts4incl. previous ratings
Rating Distribution3 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 08, 2026Initiated
RRoth Capital
Buy$8+1,024.7%
Feb 10, 2025Downgrade
DD. Boral Capital
Buy → Hold
Oct 25, 2024Upgrade
MMaxim Group
Hold → Buy$25+3,414.7%
Dec 29, 2023Initiated
CCanaccord Genuity
Buy$36+4,961.2%
Jul 07, 2021Reiterated
MMaxim Group
Buy$45 → $150+20,988.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hoffman Michael BDirectorNov 06 '26Buy1.005,000,0005,000,0008,364,883Nov 06 04:30 PM
Hoffman Michael BDirectorMay 20 '26Buy1.8776,344142,7793,364,883May 21 08:11 PM
Hoffman Michael BDirectorApr 02 '26Buy2.10713,8001,498,9803,288,539Apr 03 05:06 PM
White Mark K.DirectorApr 02 '26Proposed Sale2.087,14214,848Apr 02 04:39 PM
Hoffman Michael BDirectorDec 08 '25Buy4.3145,000193,7942,574,739Dec 08 08:05 PM
Hoffman Michael BDirectorNov 24 '25Buy4.0839,200159,8862,519,739Nov 25 12:26 PM
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs aiming to treat neurodegenerative diseases, such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. The company's product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. Annovis Bio was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
FounderDr. Maria L. Maccecchini Ph.D.
Chief Scientific OfficerDr. Cheng Fang Ph.D.
RACMs. Eve M. Damiano M.S.
Head of QualityMr. Blake Jensen M.B.A.
Senior Vice President of StatisticsMs. Hilda Maibach